3 Things Telemedicine Needs to Succeed in 2015
Research firm Kalorama Informati...
Numerous research analysts have been predicting that 2015 will see a huge increase in the integration of telemedicine.
Research firm Kalorama Information named telemedicine as one of the top five health trends for the year while IDC Health Insights projected that 65 percent of transactions with health care organizations will be mobile by 2018.
While the industry is poised to grow exponentially in the coming months, there are still some obstacles to overcome.
According to Chirag Patel, managing director of Highnote Foundry, there are three things that need to happen for telemedicine use to expand, as outlined in a recent VentureBeat article.
1. Virtual diagnosis and on-the-spot treatment are combined.
“Mobile-friendly diagnostic devices enable doctors to complete a more thorough diagnosis and provide on-the-spot treatment,” Patel wrote. “As these devices become more accessible, patient treatment can begin immediately before the patient even gets off the phone, resulting in better outcomes for the patient and the health care.”
2. The best in connected devices need to be used.
Wearables and technologies that put patients in control are growing, but this data has yet to reach all physicians for use.
“By creating a normalized set of patient and care data and by integrating these connected devices, telehealth providers can both lower the cost of care and improve overall patient outcomes,” Patel said.
He additionally advised providers to invest in scalable models of integrating data from a variety of devices, rather than relying on a single system or product alone.
3. Post-treatment care and compliance are provided.
“Prevention and compliance should be the real goals of telemedicine and are the way to truly drive significant reduction in costs,” Patel said. “To do this, providers need to understand the patient’s past medical history and also capture all of the new data associated with telemedicine into an electronic record that follows the patient.”
Monitoring patients in the first 30 days after discharge to prevent readmissions is one of the great opportunities for telemedicine and remote monitoring.
NHS opens 8 clinical trial sites to assess cancer treatment
The UK's National Health Service (NHS) is opening eight clinical trial sites to assess patients' responses to personalised cancer therapy.
The trials will analyse how patients diagnosed with advanced melanoma or non-small cell lung cancer respond to immunotherapy, to help predict their response to treatment. They will be hosted at Gloucestershire Hospitals NHS Foundation Trust facilities.
Immunotherapy helps the body's own immune system fight cancer, but while it has achieved good results for some cancer patients, it is not successful for everyone. Finding ways to predict which people will respond to the treatment is a major area of research.
OncoHost, an oncology startup, will provide advanced machine learning technology to develop personalised strategies aiming to improve the success rate of the cancer therapy. The trials will contribute to OncoHost’s ongoing PROPHETIC study, which uses the company’s host response profiling platform, PROphet®.
“Immunotherapy has achieved excellent results in certain situations for several cancers, allowing patients to achieve longer control of their cancer with maintained quality of life and longer survival,” said Dr David Farrugia, Consultant Medical Oncologist at NHS, and chief investigator of all eight NHS clinical trial sites.
“However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study is seeking to identify changes in proteins circulating in the blood which may help doctors to choose the best treatment for each patient."
"I am excited that Gloucestershire Oncology Centre and its research department have this opportunity to contribute to this growing field of research and I am determined that our centre will make a leading national contribution in patient recruitment.”
Previous studies in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with cancer will respond to various therapies.